The Development of Galectin-1 for Head and Neck Cancer

Dhanya K. Nambier, PhD
Published: Wednesday, May 24, 2017



Dhanya K. Nambiar, PhD, Stanford University, discusses the importance of continuing to study Galectin-1 for patients with head and neck cancer.

According to Nambiar, Galectin-1 is a target that should continue to be developed in combinatorial approaches so that it can eventually be investigated in clinical trials.

Additionally, it might be important to study Galectin-1 in different cancer types to determine if there is a similar correlation to what is demonstrated in head and neck cancer, states Nambiar.
 


Dhanya K. Nambiar, PhD, Stanford University, discusses the importance of continuing to study Galectin-1 for patients with head and neck cancer.

According to Nambiar, Galectin-1 is a target that should continue to be developed in combinatorial approaches so that it can eventually be investigated in clinical trials.

Additionally, it might be important to study Galectin-1 in different cancer types to determine if there is a similar correlation to what is demonstrated in head and neck cancer, states Nambiar.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder CancersApr 28, 20182.0
Publication Bottom Border
Border Publication
x